Christina DiArcangelo points out that GLP-1 drugs now come in different versions for weight loss and metabolic health, and argues they shouldn't be treated as interchangeable.
Recap by typeshit. Post by @iamchristinadiarcangelo on Instagram.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
New real-world data compares two paths for cardiovascular outcomes: stepping up the semaglutide dose or moving patients over to tirzepatide.
Novo plans oral Wegovy in France in November, and J.P. Morgan expects third-quarter sales around DKK 76 billion, about 4% above consensus. US scripts dipped for oral Wegovy and Foundayo.
Loading…